Multikinase inhibitors for treating high-risk myelodysplastic syndromes: Can this be brought into clinical practice?

Expert Review of Hematology

Volumn 6, Issue 5, 2013, Pages 485-487

  Duong, Vu H ^a   Padron, Eric ^b   List, Alan F ^b   Komrokji, Rami S ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

azanucleosides failure; investigational therapies; multikinase inhibitors; myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AXITINIB; AZACITIDINE; BCR ABL PROTEIN; DASATINIB; ERLOTINIB; IMATINIB; JANUS KINASE 2; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PLACENTAL GROWTH FACTOR; PROTEIN BCL 2; PROTEIN KINASE LYN; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RIGOSERTIB; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANOREXIA; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONSTIPATION; CONTINUOUS INFUSION; CYSTITIS; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; DYSURIA; EXPERIMENTAL THERAPY; FATIGUE; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HEMATURIA; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MEGAKARYOBLAST; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; SEPSIS; SOLID TUMOR; UPREGULATION;

ANTINEOPLASTIC AGENTS; HUMANS; MYELODYSPLASTIC SYNDROMES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84885905099     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.827884     Document Type: Review

References (20)

1. Prebet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J. Clin. Oncol. 29(24), 3322-3327 (2011).
2. Boehrer S, Galluzzi L, Lainey E et al. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 10(18), 3168-3175 (2011).
3. Komrokji RS, List AF, Yu D et al. A phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. ASH Ann. Meet. Abstr. 118(21), 1714 (2011).
4. Thepot S, Boehrer S, Prebet T et al. A phase I/II trial of erlotinib in higher risk MDS after azacitidine (AZA) failure. ASH Annual Meeting Abstracts 120(21), 1719 (2012).
5. Lainey E, Wolfromm A, Marie N et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene doi:10.1038/onc.2012.469 (2012) (Epub ahead of print).
6. Cluzeau T, Robert G, Mounier N et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget 3(4), 490-501 (2012).
7. Ozawa Y, Williams AH, Estes ML et al. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk. Res. 32(6), 893-903 (2008).
8. Duong VH, Jaglal MV, Zhang L et al. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk. Res. 37(3), 300-304 (2013).
9. Verstovsek S, Tefferi A, Cortes J et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin. Cancer Res. 14(12), 3906-3915 (2008).
10. Crump M, Hedley D, Kamel-Reid S et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk. Lymphoma 51(2), 252-260 (2010).
11. Rao AV, Rizzieri DA, Diehl LF et al. Phase II trial of sorafenib in myelodysplastic syndrome: a single institution experience. ASH Ann. Meet. Abstr. 118(21), 5021 (2011).
12. Macdonald DA, Assouline SE, Brandwein J et al. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leuk. Lymphoma 54(4), 760-766 (2013).
13. Ravandi F, Alattar ML, Levis MJ et al. Combination of sorafenib and 5-Azacytidine has significant activity in patients with relapsed/refractory or untreated acute myeloid leukemia and FLT3-ITD mutation. ASH Ann. Meet. Abstr. 120(21), 1519 (2012).
14. Giles FJ, Bellamy WT, Estrov Z et al. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk. Res. 30(7), 801-811 (2006).
15. Gumireddy K, Reddy MV, Cosenza SC et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7(3), 275-286 (2005).
16. Seetharam M, Fan AC, Tran M et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910. Na. Leuk. Res. 36(1), 98-103 (2012).
17. Olnes MJ, Shenoy A, Weinstein B et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910. Na. Leuk. Res. 36(8), 982-989 (2012).
18. Navada SC, Odchimar-Reissig R, Reddy EP, Holland JF, Wilhelm F, Silverman LR. Evaluation of rigosertib in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents: a phase I/II study. ASH Ann. Meet. Abstr. 120(21), 3794 (2012).
19. Raza A, Greenberg PL, Olnes MJ, Silverman LR, Wilhelm F. Final phase I/II results of rigosertib (ON 01910.Na) hematological effects in patients with myelodysplastic syndrome and correlation with overall survival. ASH Ann. Meet. Abstr. 118(21), 3822 (2011).
20. Komrokji RS, List AF, Wilhelm F, Lancet JE, Raza A. Oral formulation of rigosertib (ON 01910.Na) in patients with myelodysplastic syndrome (MDS)-Phase I study results. ASH Ann. Meet. Abstr. 118(21), 3797 (2011).